drugset / Trial / NCT03216278

The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

NCT03216278

Phase 1 Completed 284 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

This is a bioequivalence study of two doses of the dapagliflozin/metformin XR tablet manufactured at two different plants.

Timeline

Start
2017-09-26
Primary completion
2018-05-22
Completion
2018-05-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dapagliflozin Small molecule 5 mg Oral
Comparator Dapagliflozin Small molecule 10 mg Oral
Comparator Metformin Small molecule 500 mg Oral
Comparator Metformin Small molecule 1000 mg Oral

Indications

No indication recorded.